Substance / Medication

Sparfloxacin

Overview

Active Ingredient
sparfloxacin
RxNorm CUI
18469

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
[Etiotropic therapy with sparfloxacine in ENT practice].
Luchikhin L A, Troitskiĭ S A · Vestn Otorinolaringol · 2005
PMID: 16353009RCT
Formulation and comparative evaluation of HPMC and water soluble chitosan-based sparfloxacin nanosuspension for ophthalmic delivery.
Ambhore Nitin Prabhakar, Dandagi Panchaxari Mallapa, Gadad Anand Panchakshari · Drug Deliv Transl Res · 2016
PMID: 26545605Observational
Prevention of biofilm formation on urinary catheters: comparison of the sparfloxacin-treated long-term antimicrobial catheters with silver-coated ones.
Kowalczuk Dorota, Ginalska Grażyna, Piersiak Tomasz et al. · J Biomed Mater Res B Appl Biomater · 2012
PMID: 22903649Observational
Quantification of sparfloxacin in pharmaceutical dosages and biological samples.
Shah Jasmin, Jan Muhammad Rasul, Khan Inayatullah et al. · Pak J Pharm Sci · 2012
PMID: 23010000Observational
Development and validation of a stability-indicating RP-UPLC method for the quantitative analysis of sparfloxacin.
Gupta Himanshu, Aqil M, Khar R K et al. · J Chromatogr Sci · 2010
PMID: 20056027Observational
Effects of sparfloxacin on CNS functions and urinary hydroxyproline in mice.
Bharal Nidhi, Pillai K K, Vohora Divya · Pharmacol Res · 2006
PMID: 16701999Observational
Improvement and validation of an HPLC method for examining the effects of the MDR1 gene polymorphism on sparfloxacin pharmacokinetics.
Cho Hea-Young, Park Sun-Ae, Lee Yong-Bok · J Chromatogr B Analyt Technol Biomed Life Sci · 2006
PMID: 16530028Observational
Pharmacokinetics of topically applied sparfloxacin in rabbits.
Satia Milan C, Mody Vandana D, Modi Rajiv I et al. · Indian J Ophthalmol · 2005
PMID: 16137962Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sparfloxacin (substance)
SNOMED CT
387554008
UMLS CUI
C0052585
RxNorm CUI
18469

Clinical Data

This intervention maps to 14 entities in the Healos knowledge graph.

9
Conditions
2
Biomarkers
2
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.